Panel Discussion: Ensuring Product Safety When Moving Into the Clinic

Time: 10:00 am
day: Day 1 AM

Details:

• Outlining a checklist of necessary steps for comprehensively demonstrating product safety
• Practical steps for validating the specificity of a CRISPR/Cas therapy
• Safety experiments, analysis, and presentation to regulators to transition into the clinic
• Key considerations for product safety profiling with different delivery approaches

Speakers:

TJ Cradick

Ryan Leenay Ryan is the head of gene editing at Eli Lilly & Co, within the genetic medicine business unit. Lilly has internal programs and external editing Read more

Laura Serwer Dr. Serwer leads the in vivo pharmacology and toxicology teams at CRISPR Therapeutics, and her team has lead nonclinical safety efforts for multiple INDs/CTAs for Read more